Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1713932

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the paper entitled The Future of Clinical Research Delivery: 2022 to 2025 implementation plan, published on 30 June 2022, what progress has been made on the Find, Recruit and Follow-up service for clinical trials.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	23739
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>Since publication of the Future of Clinical Research Delivery, we have developed early versions of several products as part of the Find, Recruit and Follow-up Service, to deliver secure data enabled study feasibility and recruitment within established governance and legal requirements, across England and other parts of the United Kingdom.</p><p> </p><p>These products include: NHS England’s DigiTrials self-service feasibility tool, which identifies suitable locations for studies by establishing where the largest groupings of eligible people are based; NHS England’s DigiTrials recruitment service, which is currently in its second phase of pilots and will enable the National Health Service to more easily approach patients about research relevant to them; the Medicines and Healthcare products Regulatory Agency’s Clinical Research Practice Datalink, which allows participating general practices to identify potentially eligible patients for relevant studies more easily; and the Be Part of Research registry, which allows people to proactively register their interest in participating in research.</p><p> </p><p>These tools have been developed to increase the efficiency and effectiveness of the clinical research process, and also improve our ability to widen access to research opportunities, increase the resilience and sustainability of the healthcare system, and reduce the burden on the NHS workforce.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 30/04/2024 10:48:51 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1713933

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials: Contracts
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled Full government response to the Lord O'Shaughnessy review into commercial clinical trials, last updated on 8 December 2023, what her Department's planned timetable is for expanding the national contract value review programme to phase 1 and 2a clinical trials.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	23740
answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>The National Contract Value Review (NCVR) process applies to commercial clinical studies. NHS England is working in partnership with the devolved administrations, the National Institute for Health and Care Research, and other partners, to pilot the use of the NCVR process for phase I and IIa of commercial clinical trials. The ambition is to make the use of NCVR for phase I and IIa of commercial clinical trials mainstream from October 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 30/04/2024 09:57:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1694639

registered interest
date	07/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Oesophageal Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has made an assessment of the potential merits of increasing the use of the capsule sponge test to detect oesophageal cancer.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	17597
answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>NHS England commissioned an evaluation to assess the impact of the capsule sponge test in secondary care, for patients on a routine reflux pathway. The evaluation report was completed in September 2023 and the national pilot will conclude in March 2024.</p><p>On 26 February 2024, NHS England published the results of the capsule sponge test pilot for secondary care routine reflux and Barrett’s surveillance cohort, which began in January 2021, and launched at 30 hospitals across England. The pilot tested over 8,500 patients with the capsule sponge test. Evaluation of a cohort of patients showed almost eight out of 10 patients, who completed a test, were discharged without the need for further testing, freeing up endoscopy capacity for higher risk patients and those referred for urgent tests for oesophageal cancer. Patients with positive results from the capsule sponge test who were referred on for an endoscopy had the highest prevalence of Barrett’s oesophagus, at 27.2%, compared to zero patients with negative results who completed an endoscopy.</p><p>NHS England has not committed to national uptake of capsule sponge, but will continue to support integrated care boards (ICBs) and local systems to deliver in their area. The evaluation report was published and shared with local National Health Service systems including Cancer Alliances, NHS providers, and ICBs to support with local service provision. The evaluation findings should be interpreted and used locally, based on need.</p><p>NHS England is continuing to explore other capsule sponge use cases, including in primary and community care settings jointly funded by the National Institute for Health and Care Research and Cancer Research UK. Separately to this, the CYTOPRIME2 project is funded through the NHS Cancer Programme’s Innovation Open Call and is assessing the feasibility and safety of using capsule sponge in a primary care setting, and evaluating key outcome metrics.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/03/2024 10:11:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1694641

registered interest
date	07/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Disease Control: Staff
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many full-time equivalent members of staff work on pandemic preparedness in (a) her Department and (b) the UK Health Security Agency.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	17599
answer	answer is ministerial correction date of answer 25/03/2024 answer text <p>The Government continues to plan and prepare for a range of pandemic and emerging infectious disease scenarios, including those caused by respiratory contact, both influenza and non-influenza, and vector-borne pathogens, building on lessons learned from exercises and incidents, including the COVID-19 pandemic. There are currently 21.35 full time equivalent (FTE) staff working on pandemic preparedness within the Global and Public Health Group of the Department.</p><p>Every team across the United Kingdom Health Security Agency (UKHSA) is playing a critical role in the nation’s pandemic preparedness and is committing significant resource and effort to meet our remit. As a result, it is not possible to provide an FTE figure of all staff whose work forms part of pandemic preparedness. The UKHSA’s Centre for Pandemic Preparedness (CPP) holds some members of staff who are focused primarily on pandemic preparedness policy and coordination. There currently are 18.4 FTEs working in CPP.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 25/03/2024 11:59:36 answering member 4492 label Biography information for Maria Caulfield
tabling member	4124 label Biography information for Chi Onwurah